<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554836</url>
  </required_header>
  <id_info>
    <org_study_id>4213000</org_study_id>
    <nct_id>NCT04554836</nct_id>
  </id_info>
  <brief_title>MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab</brief_title>
  <official_title>Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TheraOp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TheraOp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate&#xD;
      the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line&#xD;
      therapy to patients with RAS (Rat sarcoma)-mutant mCRC (Metastatic colorectal cancer)&#xD;
      diagnosis who convert to RAS wild-type using monitoring of the RAS mutation status by liquid&#xD;
      biopsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From date of randomization up to 24 months</time_frame>
    <description>Evaluation of efficacy in terms of progression free survival (PFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization up to 24 months.</time_frame>
    <description>In experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure of treatment strategy (TFTS)</measure>
    <time_frame>After randomization up to 24 months.</time_frame>
    <description>In experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (progression free survival) rate</measure>
    <time_frame>1 year after date of randomization</time_frame>
    <description>In experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of response</measure>
    <time_frame>From the start of the first line treatment in the study up to 24 months.</time_frame>
    <description>In terms of reduction of tumor mass in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis resections.</measure>
    <time_frame>From the start of the first line treatment in the study up to 24 months.</time_frame>
    <description>In experimental and control arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From the start of the first line treatment in the study up to 24 months.</time_frame>
    <description>Defined as patients with partial or complete response (CR or PR) in experimental and control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>From the date of signature of Informed Consent to 24 months.</time_frame>
    <description>According to CTCAE (Common Terminology Criteria of Adverse Events), Version 5.0 criteria in experimental and control arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of driver mutations.</measure>
    <time_frame>From the start of the first line treatment in the study up to 24 months.</time_frame>
    <description>In patients with progressive disease (PD) under cetuximab therapy who remain RAS (Rat sarcoma) wild-type in liquid biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison the efficacy in terms of progression free survival (PFS)</measure>
    <time_frame>From the start of the first line treatment in the study up to 24 months.</time_frame>
    <description>In patients with conversion to RAS (RAt sarcoma) wild-type in both ddPCR (Droplet Digital PCR) BEAMing with those patients showing conversion to RAS wild-type in ddPCR but not in BEAMing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <arm_group>
    <arm_group_label>FOLFIRI + cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Arm A will receive FOLFIRI + cetuximab until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first. The recurrence of RAS-mutation without PD to switch back to FOLFIRI. In case of repeated conversion to RAS wild-type without PD, treatment will shift to FOLFIRI + cetuximab again, and so on. Switches of treatment will proceed until progressive disease (PD), unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.&#xD;
[FOLFIRI = Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Arm B will continue therapy with FOLFIRI until PD, unacceptable toxicity, withdrawal of informed consent or death, whatever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Patients in Arm A will receive FOLFIRI +cetuximab.</description>
    <arm_group_label>FOLFIRI + cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)</description>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI + cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, UICC stage IV adenocarcinoma of the left-sided colon or&#xD;
             rectum with metastases (metastatic colorectal cancer), primarily non-resectable,&#xD;
             confirmed RAS mutations proven in the primary tumor or metastasis (KRAS ans NRAS exon&#xD;
             2, 3, 4)&#xD;
&#xD;
          -  Age ≥ 18 years on day of signing informed consent&#xD;
&#xD;
          -  No previous chemotherapy for metastatic disease (1- 2 cycles FOLFIRI or mFOLFIRI are&#xD;
             permitted before enrolment until RAS status is determined)&#xD;
&#xD;
          -  Patients suitable for chemotherapy administration&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) status 0-1&#xD;
&#xD;
          -  Consent to liquid biopsy and mutation analysis&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Presence of at least one measurable reference lesion according to the RECIST 1.1&#xD;
             criteria (chest CT and abdominal CT 4 weeks or less before enrollment)&#xD;
&#xD;
          -  Adequate bone marrow function defined as: Leukocytes 3.0 x 10 9/L with neutrophils 1.5&#xD;
             x 10 9/L, Thrombocytes 100 x 10 9/L, Hemoglobin 9 g/dL&#xD;
&#xD;
          -  Adequate hepatic function defined as: Serum bilirubin 1.5 x ULN (Upper limit of&#xD;
             normal), ALAT (Alanine-aminotransferase (= SGPT = serum glutamate pyruvate&#xD;
             transaminase) and ASAT (aspartate-aminotransferase (= SGOT = serum glutamate&#xD;
             oxalacetate transaminase) 2.5 x ULN (Upper limit of normal) (in the presence of&#xD;
             hepatic metastases, ALAT and ASAT 5 x ULN)&#xD;
&#xD;
          -  Adequate renal function: Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Adequate cardiac function defined as Normal ECG and echocardiogram with a left&#xD;
             ventricular ejection fraction (LVEF) of 55%&#xD;
&#xD;
          -  INR (International normalized ratio) &lt; 1.5 and aPTT (activated Partial thromboplastin&#xD;
             time) &lt; 1.5 x ULN (patients without anticoagulation). Therapeutic anticoagulation is&#xD;
             allowed if INR and aPTT have remained stable within the therapeutic range for at least&#xD;
             2 weeks.&#xD;
&#xD;
          -  Time interval of at least 6 months since last administration of any previous&#xD;
             neoadjuvant/adjuvant chemotherapy or radiochemotherapy of the primary tumor in&#xD;
             curative treatment intention to start of 1st line treatment&#xD;
&#xD;
          -  Any relevant toxicities of prior treatments must have resolved to grade ≤ 1 according&#xD;
             to the CTCAE (version 5), except alopecia&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) should have a negative urine pregnancy test&#xD;
             within 72 hours prior to receiving the first dose of study medication.&#xD;
&#xD;
          -  Highly effective contraception for both male and female patients throughout the study&#xD;
             and for at least 3 months after last dose of study medication administration if the&#xD;
             risk of conception exists. Highly effective contraception has to be in line with the&#xD;
             definition of the CTFG (Clinical Trial Facilitation Group) recommendation&#xD;
&#xD;
          -  Signed written informed consent and capacity of understanding the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Right sided mCRC&#xD;
&#xD;
          -  Primarily resectable metastases&#xD;
&#xD;
          -  Previous chemotherapy for the colorectal cancer with the exception of adjuvant&#xD;
             treatment, completed at least 6 months before entering the study (1- 2 cycles FOLFIRI&#xD;
             or mFOLFIRI are permitted before enrolment)&#xD;
&#xD;
          -  Patients with known brain metastases&#xD;
&#xD;
          -  Symptomatic peritoneal carcinosis&#xD;
&#xD;
          -  Progressive disease before randomization&#xD;
&#xD;
          -  History of acute or subacute intestinal occlusion, inflammatory bowel disease, immune&#xD;
             colitis or chronic diarrhea&#xD;
&#xD;
          -  Grade II heart failure (NYHA classification), Myocardial infarction, balloon&#xD;
             angioplasty (PTCA) with or without stenting, and cerebral vascular accident/stroke&#xD;
             within the past 12 months before enrollment, unstable angina pectoris, serious cardiac&#xD;
             arrhythmia according to investigator's judgment requiring medication&#xD;
&#xD;
          -  Active infection with hepatitis B or C&#xD;
&#xD;
          -  Medical or psychological impairments associated with restricted ability to give&#xD;
             consent or not allowing conduct of the study&#xD;
&#xD;
          -  Additional cancer; Exceptions include adequately treated basal cell carcinoma of the&#xD;
             skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has&#xD;
             undergone potentially curative therapy without evidence of recurrence&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Marked proteinuria (nephrotic syndrome)&#xD;
&#xD;
          -  Arterial thromboembolism or severe hemorrhage within 6 months prior to randomization&#xD;
             (with the exception of tumor bleeding before tumor resection surgery)&#xD;
&#xD;
          -  Hemorrhagic diathesis or tendency towards thrombosis&#xD;
&#xD;
          -  Participation in a clinical study or experimental drug treatment within 30 days prior&#xD;
             to study&#xD;
&#xD;
          -  Known hypersensitivity or allergic reaction to any of the study medications&#xD;
&#xD;
          -  Severe, non-healing wounds, ulcers, bone fractures or an infection requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Known history of alcohol or drug abuse&#xD;
&#xD;
          -  Complete dihydropyrimidine dehydrogenase (DPD) deficiency (phenotype and/or genotype&#xD;
             test) (Patients with partial DPD deficiency may be included in this clinical trial at&#xD;
             the discretion of the investigator and should receive a reduced starting 5-FU dose)&#xD;
&#xD;
          -  Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not&#xD;
             required)&#xD;
&#xD;
          -  Absent or restricted legal capacity&#xD;
&#xD;
          -  For female patients only: Pregnancy (absence to be confirmed by ß-HCG test) or&#xD;
             lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum (Dachau II)</name>
      <address>
        <city>Dachau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken-Essen-Mitte Evang. Huyssens-Stiftung</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>https://www.frontiersin.org/articles/10.3389/fonc.2020.01115/full?report=reader</url>
    <description>Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer.</description>
  </link>
  <results_reference>
    <citation>Klein-Scory S, Wahner I, Maslova M, Al-Sewaidi Y, Pohl M, Mika T, Ladigan S, Schroers R, Baraniskin A. Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. Front Oncol. 2020 Jul 16;10:1115. doi: 10.3389/fonc.2020.01115. eCollection 2020.</citation>
    <PMID>32766143</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left sided Adenocarcinoma of the Colon</keyword>
  <keyword>RAS mutated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

